Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT00946153 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib

Sponsor

Eisai Co., Ltd.